Wegovy

Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus, is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management, developed by Novo Nordisk in 2012.Semaglutide is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control.

Read more in the app

Drugs like Wegovy can be effective at treating fatty liver disease

Ozempic and Wegovy ingredient may reverse signs of liver disease

Why Ozempic and Wegovy Might Change Your Favorite Food

Daily pill could replace weight-loss shots like Ozempic and Wegovy

Drugs like Ozempic and Wegovy could significantly cut dementia risk

Trump Rejects Proposal for Medicare to Cover Wegovy and Other Obesity Drugs

Do Ozempic and Wegovy really cause hair loss?

How Much Should Weight Loss Drugs Like Wegovy and Zepbound Cost?

Weight-loss jabs may help reduce alcohol intake, study finds - First clinical trial of its kind has found that semaglutide, distributed under the brand name Wegovy, cut the amount of alcohol people drank by about 40% and dramatically reduced people’s desire to drink.

Strongest evidence yet that Ozempic and Wegovy reduce alcohol intake

Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy

Ozempic and Wegovy: Scientists Uncover New Risks of Popular Weight-Loss “Miracle Drugs”

Ozempic and Wegovy have heart health benefits beyond just weight loss

Why do Ozempic and Wegovy seem to treat everything?

Not Just Weight Loss: 8 Conditions Drugs Like Wegovy Might Treat

Ozempic and Wegovy may help curb alcohol addiction, study suggests

Ozempic and Wegovy Ease Knee Osteoarthritis Pain in Large Study

Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: Study

Wegovy's Older Cousin Could Soon Be Sold Cheap. Here's How They Compare.

Does Semaglutide (Ozempic/Wegovy) Harm Your Mental Health? New Study Says No